JGC
LUMO

J. Goldman & Co’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

J. Goldman & Co’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6,111
Closed -$1.33M – 431
2017
Q1 		$1.33M Buy
+6,111
New +$873K 0.07% 239

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

J. Goldman & Co's LUMO Position: Q2 2017 in Review

J. Goldman & Co sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2017, closing a stake of 6,111 shares — an estimated $1.33M sold.

J. Goldman & Co first reported a position in LUMO in Q1 2017 and held it in 1 quarter. The position peaked at $1.33M in Q1 2017. 110 funds tracked by Wall St. Rank hold LUMO as of Q2 2017.

  • J. Goldman & Co reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • J. Goldman & Co sold 6,111 Lumos Pharma, Inc. Common Stock shares in Q2 2017, an estimated $1.33M.
  • J. Goldman & Co first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • J. Goldman & Co's Lumos Pharma, Inc. Common Stock position peaked at $1.33M in Q1 2017.
  • 110 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2017.

Based on J. Goldman & Co's 13F filing for Q2 2017, filed 14 Aug 2017.